Company: LRHC
Filing Date: 2025-09-30
Form Type: 424B3
Source: 0001213900-25-093998
Chunk: 28

Company: La Rosa Holdings Corp.
Filing Date: 2025-09-30
Form: 424B3
Chunk 28
---
-K, Quarterly Reports on Form 10-Q and in our other periodic reports are not the only ones that we face. Additional risks not presently known to us or that we currently deem immaterial may also adversely affect our business operations.

Risks Related to this Offering

The sale of the shares of common stock acquired by the Selling Stockholder, or the perception that such sales may occur, could cause the price of our common stock to decrease.

On September 18, 2025, we entered into the Amended Facility Agreement
with the Selling Stockholder, pursuant to which the Selling Stockholder committed to purchase up to $1,000,000,000 of our common stock.
The shares that we may issue and sell to the Selling Stockholder under the Facility may be sold by us to the Selling Stockholder from
time to time at our discretion over a 36-month period commencing on August 5, 2025. The purchase price for the shares that we may issue
and sell to the Selling Stockholder under the Facility will vary based on the price of our common stock at the time we initiate the sale.
Depending on market liquidity at the time, sales of such shares may cause the trading price of our common stock to decrease.

We generally have the right to control the timing
and amount of any future sales of our shares to the Selling Stockholder. Sales of shares of our common stock to the Selling Stockholder under the Facility, if any, will depend
upon market conditions and other factors to be determined by us. We may ultimately decide to sell to the Selling Stockholder all, some or none of the shares
of our common stock that may be available for us to sell pursuant to the Facility. If and when we do sell shares to the Selling Stockholder, after the Selling Stockholder has
acquired the shares, the Selling Stockholder may resell all, some or none of those shares at any time or from time to time in its discretion. Therefore,
sales to the Selling Stockholder by us could result in substantial dilution to the interests of other holders of our common stock. Additionally, the sale
of a substantial number of shares of our common stock to the Selling Stockholder, or the anticipation of such sales, could make it more difficult for us
to sell equity or equity-related securities in the future at a time and at a price that we might otherwise wish to effect sales.

Sales of a substantial number of our securities in the public market by the Selling Stockholder and/or by our existing securityholders